Biologics Spine Cerapedics Announces First U.S. Patient Treated with PearlMatrix™ P-15 Peptide Enhanced Bone Graft following FDA approval byTim AllenJuly 8, 2025
Regulatory Spine Cerapedics Announces FDA Approval of PearlMatrix™ P-15 Peptide Enhanced Bone Graft, The First and Only Proven Bone Growth Accelerator for Lumbar Fusion byJosh SandbergJune 23, 2025
Biologics Spine Cerapedics’ i-FACTOR P-15 Peptide Enhanced Bone Graft, a Trusted Choice in Bone Graft Solutions, Now Approved for Expanded Indications for Use byJosh SandbergSeptember 24, 2024
Biologics Spine Top Stories Cerapedics Files Final Module of the PMA Application for FDA Approval of a new P-15 Peptide Enhanced Bone Graft for Lumbar Spine Fusion byJosh SandbergJanuary 4, 2024
Biologics Spine Cerapedics Reinforces Commitment to Level 1 Evidence with Long-Term Results from Six-Year Pivotal IDE Cervical Study Demonstrating 98.6% Spine Fusion Rates in Patients Treated With i-FACTOR® byJosh SandbergOctober 17, 2023
Biologics Spine Cerapedics™ Announces Expansion of Headquarters to Support Growth of its Bone Graft Products byJosh SandbergJuly 19, 2023
Biologics Spine Top Stories Cerapedics Appoints Valeska Schroeder Chairman and Chief Executive Officer byJosh SandbergOctober 10, 2022
Biologics Top Stories Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft byChris StewartFebruary 24, 2022
Biologics Spine Top Stories Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery byJosh SandbergAugust 17, 2021
Biologics Regulatory Spine Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease byJosh SandbergApril 29, 2021
